Literature DB >> 12588381

The Children's Dermatology Life Quality Index: validation of the cartoon version.

S A Holme1, I Man, J L Sharpe, P J Dykes, M S Lewis-Jones, A Y Finlay.   

Abstract

BACKGROUND: In 1995 the Children's Dermatology Life Quality Index (CDLQI) was developed as a tool to allow quality of life assessment of children with skin conditions. This initial questionnaire was in a written format.
OBJECTIVES: Using the same validated questions, a full-colour cartoon version has been developed. The aim of this study was to validate this against the initial written questionnaire in a three-part study.
METHODS: The first part of the study piloted the use of both versions in an outpatient setting. One hundred and one children completed both versions of the CDLQI in a random order. A further 66 children completed the cartoon CDLQI in outpatients, and subsequently completed the cartoon version on the same day at home, which was returned by post. The scores were compared. In the second part, in more controlled conditions to eliminate parental and investigator bias, 107 children with current dermatological problems were administered both versions of the CDLQI in a random order. The scores were analysed, and time to complete each version, and the child and parental preferences, were recorded. The third part assessed compliance by asking 546 children recently reviewed in dermatology clinics to return a single completed postal CDLQI. Half of the children were given the text, and half the cartoon version.
RESULTS: The median age of participating children was 11 years. There was no significant difference in scores between the two versions in both parts 1 and 2, but the cartoon version was completed faster (median 90 s) than the written version (median 120 s) (P < 0.0001). Both children and their parents significantly preferred the cartoon version and found it easier to use. Forty-six per cent of the postal CDLQI questionnaires were returned; there was no difference in compliance between the two versions.
CONCLUSIONS: The cartoon CDLQI is equivalent to the previously validated written CDLQI version, but is faster and easier for children to use, and is preferred by both children and parents.

Entities:  

Mesh:

Year:  2003        PMID: 12588381     DOI: 10.1046/j.1365-2133.2003.05157.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

Review 1.  Characteristics of health-related self-report measures for children aged three to eight years: a review of the literature.

Authors:  Joanne Cremeens; Christine Eiser; Mark Blades
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

Review 2.  Quality-of-life outcomes and measurement in childhood atopic dermatitis.

Authors:  Sarah L Chamlin; Mary-Margaret Chren
Journal:  Immunol Allergy Clin North Am       Date:  2010-07-01       Impact factor: 3.479

3.  Favorable effects of explanatory illustrations attached to a self-administered questionnaire for upper extremity disorders.

Authors:  Shigeru Kurimoto; Michiro Yamamoto; Takaaki Shinohara; Masahiro Tatebe; Iwatsuki Katsuyuki; Hitoshi Hirata
Journal:  Qual Life Res       Date:  2012-07-22       Impact factor: 4.147

4.  Psychometric properties of the Children's Dermatology Life Quality Index in pediatric localized scleroderma.

Authors:  Kaveh Ardalan; Galen E Switzer; Christina K Zigler; Nicole M Hershey; Kathryn S Torok
Journal:  J Scleroderma Relat Disord       Date:  2018-03-20

5.  The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Suzanne Li; Kathleen M O'Neil; Elena Pope; Gloria C Higgins; Marilynn Punaro; Egla C Rabinovich; Margalit Rosenkranz; Daniel A Kietz; Paul Rosen; Steven J Spalding; Teresa R Hennon; Kathryn S Torok; Elaine Cassidy; Thomas A Medsger
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

6.  Correlates of self-reported quality of life in adults and children with morphea.

Authors:  Shinjita Das; Ira Bernstein; Heidi Jacobe
Journal:  J Am Acad Dermatol       Date:  2014-02-16       Impact factor: 11.527

Review 7.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

8.  A Prospective Controlled Study on Long-Term Outcomes of Facial Lacerations in Children.

Authors:  Sonja Fontana; Clemens M Schiestl; Markus A Landolt; Georg Staubli; Sara von Salis; Kathrin Neuhaus; Christoph Mohr; Julia Elrod
Journal:  Front Pediatr       Date:  2021-02-12       Impact factor: 3.418

Review 9.  Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.

Authors:  Balvinder Rehal; April W Armstrong; April Armstrong
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

Review 10.  Counting the Burden: Atopic Dermatitis and Health-related Quality of Life.

Authors:  Faraz Ali; Jui Vyas; Andrew Y Finlay
Journal:  Acta Derm Venereol       Date:  2020-06-09       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.